Delivery Order 36C26223D0011-36C26226N0176
- Not listed
- This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 22 to JRS Pharma LP, a for-profit manufacturer of goods. The $65,286.00 firm fixed price delivery order contract is for the provision of PROSOLV EASYTAB SP, a pharmaceutical excipient product. This award is part of an ongoing indefinite delivery vehicle (IDV) contract between JRS Pharma LP and the VA VHA Veterans Integrated Service Network...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 awarded a $11,724.80 firm fixed price delivery order contract to JRS Pharma LP of Patterson, New York. The one-year contract, running from December 1, 2023 through November 30, 2024, is for the purchase of PROSOLV EASYTAB SP. As the Veterans Health Administration provides healthcare services to military veterans, this contract will supply JRS Pharma's PROSOLV EASYTAB SP product to various...
- JRS Pharma LP has been awarded a $49,298.80 firm fixed price delivery order for ProSolv EasyTab under the Department of Veterans Affairs' Veterans Health Administration contract vehicle. The order is for the continued provision of ProSolv EasyTab to the Veterans Integrated Service Network 22 in Patterson, New York, with performance through November 30, 2023. ProSolv EasyTab has been consistently provided by JRS Pharma to the VA-VHA over multiple contract years, indicating customer satisfaction...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a delivery order contract to JRS Pharma LP for the provision of the "ProSolv EasyTab" product. The $408,630.00 firm-fixed price contract has been in place since July 17, 2017, with the most recent delivery order issued on July 16, 2022. The contract does not have a set-aside designation. The recurring nature of the delivery orders suggests the VA-VHA has an ongoing need for this product from the...
- Otsuka America Pharmaceutical Inc. received a delivery order valued at $282,855.34 from the Department of Veterans Affairs' Veterans Integrated Service Network 22 for Jynarque (tolvaptan), a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia. Issued on July 1, 2022, with a completion date of June 30, 2023, this firm fixed-price delivery order was placed under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and carried no...
- Otsuka America Pharmaceutical Inc., a Maryland-based specialty pharmaceutical manufacturer, was awarded a firm fixed price delivery order valued at $12,195.72 by Veterans Integrated Service Network 5 (VISN 5) on October 4, 2023, with an ultimate completion date of October 6, 2023. The contract calls for the delivery of Jynarque (tolvaptan) in 90mg/30mg dosages to support the Department of Veterans Affairs' healthcare operations in Pittsburgh, Pennsylvania. This delivery order operates under...
- Otsuka America Pharmaceutical Inc., a specialty pharmaceutical manufacturer headquartered in Rockville, Maryland, received a delivery order award from the Department of Veterans Affairs (VA) Veterans Integrated Service Network 5 on March 8, 2023, for the supply of Jynarque (tolvaptan) 60mg/30mg. This firm-fixed-price contract, valued at $12,195.72, carries an ultimate completion date of March 10, 2023, and is issued for delivery to Pittsburgh, Pennsylvania. The award is issued under the VA's...
- Otsuka America Pharmaceutical Inc., a pharmaceutical manufacturer headquartered in Rockville, Maryland, received a delivery order award from the Department of Veterans Affairs' Veterans Integrated Service Network 6 on June 23, 2022, for the supply of Jynarque (tolvaptan). This firm-fixed price delivery order has a ceiling value of approximately $137K and is scheduled for completion by September 30, 2022. The award represents performance under the parent GSA Schedule contract for...
- On July 1, 2023, the Department of Veterans Affairs (VA), specifically Veterans Integrated Service Network 22, awarded a delivery order to Otsuka America Pharmaceutical Inc. for Jynarque (tolvaptan) with a ceiling value of $284,695.42. This firm fixed-price delivery order, with an ultimate completion date of June 30, 2024, was issued without set-aside designation under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract supports the VA's provision of specialty...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $1,136.12 by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Journavx 50 mg tablets (30-count packaging). The contract is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- 36C26223D0011Indefinite Delivery Contract
- 36C26223D0011-36C26226N0176Delivery Order
JRS Pharma LP, a pharmaceutical excipient manufacturer based in Patterson, New York, has been awarded a delivery order valued at $60,752.00 for PROSOLV EASYTAB SP under an Indefinite Delivery Contract with the Department of Veterans Affairs Veterans Health Administration, specifically Veterans Integrated Service Network 22. This delivery order, issued on December 1, 2025, with an ultimate completion date of November 30, 2026, represents a firm fixed price contract with no set-aside designation. The award is part of a larger single-award IDC valued at $247,009.80 that ensures continued supply of this pharmaceutical excipient to VA medical facilities serving military veterans within the region through November 30, 2025. PROSOLV EASYTAB SP is a pharmaceutical excipient—an inactive ingredient used in tablet formulation and drug delivery—that supports the VA's healthcare operations. JRS Pharma LP has maintained an exclusive supplier relationship with Veterans Integrated Service Network 22, delivering pharmaceutical products through multiple delivery orders under the IDC framework. This arrangement enables the VA to secure reliable supply chain management for specialized pharmaceutical components critical to patient care and treatment programs across its medical facilities in the service network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $60.8k | 11/7/25 |